ClinicalTrials.gg

Program

Interleukin 1 Receptor Antagonist Protein

Also written as “Anakinra”, “Anakinra (Kineret®)” and “anakinra”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Familial Mediterranean Fever · COVID-19 · Still's Disease, Adult-Onset, led by 3 companies.

Furthest: phase 4, since May 20, 200514 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen70 open or runningphase 4since May 20, 2005May 17, 2002none ahead
Swedish Orphan Biovitrum61 open or runningphase 4since Oct 8, 2024Dec 13, 2016none ahead
Hamad Medical10 open or runningphase 3since Nov 24, 2020Nov 24, 2020none ahead

Also a collaborator on its studies: Tigermed Consulting and CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2002First studies: 3 phase 2 studiesNew to AmgenAmgen · NCT00037648, NCT00037700, NCT00038298
  2. May 16, 2005Phase 2 study in OsteoarthritisAmgen · NCT00110916 · 165 enrolled
  3. May 20, 2005Phase 4 study in Arthritis, RheumatoidAmgen · NCT00111410
  4. Jun 30, 2005Phase 4 study in Arthritis, RheumatoidAmgen · NCT00121043
  5. Jun 30, 2005Phase 3 study in Arthritis, RheumatoidAmgen · NCT00117091
  6. Dec 13, 2016Swedish Orphan Biovitrum’s first study: phase 2 study in GoutNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT03002974 · 165 enrolled · United States
  7. Aug 25, 2017Phase 3 study in Still's Disease, Adult-OnsetSwedish Orphan Biovitrum · NCT03265132 · 13 enrolled · United States, Canada
  8. Mar 25, 2020Phase 3 study in SARS-CoV-2Swedish Orphan Biovitrum · NCT04324021 · 16 enrolled · United States, Italy
  9. Nov 24, 2020Hamad Medical’s first study: phase 3 study in COVID-19New to Hamad MedicalHamad Medical · NCT04643678 · 80 enrolled · Qatar
  10. Nov 22, 2022Phase 3 study in Arthritis, JuvenileSwedish Orphan Biovitrum · NCT05814159 · 15 enrolled · Japan
  11. Oct 8, 2024Phase 4 study in Familial Mediterranean FeverSwedish Orphan Biovitrum · NCT06666335
  12. Jun 24, 2026Phase 4 study in Arthritis, JuvenileSwedish Orphan Biovitrum · NCT07706868

TargetBeta

IL1A →read by rule
“A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist ”NCIt, by rule

Other programs on IL1A

ProgramCompanyFurthest phaseStudies
lutikizumabAbbViephase 312
ABBV-1451AbbViephase 11

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07706868Arthritis, Juvenile4WithdrawnSwedish Orphan BiovitrumSep 30, 20280
NCT06666335Familial Mediterranean Fever4WithdrawnSwedish Orphan BiovitrumAug 30, 20270
NCT05814159Arthritis, Juvenile · Japan3Active, not recruitingSwedish Orphan BiovitrumDec 10, 202515
NCT04643678COVID-19 · Qatar3CompletedHamad MedicalMar 1, 202180
NCT04324021SARS-CoV-2 · United States, Italy3TerminatedSwedish Orphan BiovitrumNov 13, 202016
NCT03265132Still's Disease, Adult-Onset · United States, Canada3TerminatedSwedish Orphan BiovitrumFeb 13, 201913
NCT03002974Gout · United States2CompletedSwedish Orphan BiovitrumJun 2018165
NCT00121043Arthritis, Rheumatoid4CompletedAmgen
NCT00117091Arthritis, Rheumatoid3CompletedAmgen
NCT00111410Arthritis, Rheumatoid4CompletedAmgen
NCT00110916Osteoarthritis2CompletedAmgenFeb 2005165
NCT00038298Arthritis, Rheumatoid2CompletedAmgenMay 200453
NCT00037700Arthritis, Rheumatoid2CompletedAmgen
NCT00037648Arthritis, Juvenile2CompletedAmgenNov 200386

How it is read

Names in the registry

  • “Anakinra”, 5 entries
  • “Anakinra (Kineret®)”, 2 entries
  • “anakinra”, 2 entries
  • “AMG 719”, 2 entries
  • “Anakinra 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.